<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRI-ESTARYLLA- norgestimate and ethinyl estradiol 
			 </strong><br>Sandoz Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Tri-Estarylla™ safely and effectively.  See full prescribing information for Tri-Estarylla™.<br>Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP), for oral use<br>Initial U.S. Approval: 1989</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Tri-Estarylla™ is contraindicated in women over 35 years old who smoke. (4)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Cigarette smoking increases the risk of serious    cardiovascular events from combination oral contraceptives (COC) use. (4)</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Tri-Estarylla™ is contraindicated in women over 35 years old who smoke. (4)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Cigarette smoking increases the risk of serious    cardiovascular events from combination oral contraceptives (COC) use. (4)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP),is an estrogen/progestin COCs, indicated for use by women to prevent pregnancy. (<a href="#_Ref">1.1</a>) </p>
<p class="Highlighta">Tri-Estarylla™ is also indicated for the treatment of moderate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>. </p>
<p class="Highlighta">Tri-Estarylla™ should be used for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> only if the patient desires an oral contraceptive for birth control. (<a href="#ID_bc789972-cef7-4fd9-bb1f-40be635366f8">1.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Take one tablet daily by mouth at the same time every day. (<a href="#ID_a647c8d9-7db4-4413-a452-bd61b24e6c86">2.2</a>)</dd>
<dt>•</dt>
<dd>Take tablets in the order directed on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. (<a href="#ID_a647c8d9-7db4-4413-a452-bd61b24e6c86">2.2</a>)</dd>
<dt>•</dt>
<dd>Do not skip or delay tablet intake. (<a href="#ID_a647c8d9-7db4-4413-a452-bd61b24e6c86">2.2</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP) consists of 28 tablets in the following order (<a href="#ID_54cd9a6c-4832-440e-8dbc-1b18abaab03a">3</a>): </p>
<dl>
<dt>•</dt>
<dd>7 white tablets each containing 0.18 mg norgestimate and 0.035 mg ethinyl estradiol</dd>
<dt>•</dt>
<dd>7 light blue tablets each containing 0.215 mg norgestimate and 0.035 mg ethinyl estradiol</dd>
<dt>•</dt>
<dd>7 blue tablets each containing 0.25 mg norgestimate and 0.035mg of ethinyl estradiol</dd>
<dt>•</dt>
<dd>7 green tablets (inert)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>A high risk of arterial or venous thrombotic diseases (<a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span> or liver disease (<a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">4</a>)</dd>
<dt>•</dt>
<dd>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> (<a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">4</a>)</dd>
<dt>•</dt>
<dd>Pregnancy (<a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">4</a>)</dd>
<dt>•</dt>
<dd>Breast cancer or other estrogen- or progestin-sensitive cancer (<a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Thromboembolic Disorders and Other Vascular Problems: Stop Tri-Estarylla™ if a thrombotic event occurs. Stop at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. (<a href="#_Ref">5.1</a>)</dd>
<dt>•</dt>
<dd>Liver disease: Discontinue Tri-Estarylla™ if <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs. (<a href="#ID_49d51c87-7f56-447b-b452-d5828da3cc15">5.2</a>)</dd>
<dt>•</dt>
<dd>High blood pressure: If used in women with well-controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, monitor blood pressure and stop Tri-Estarylla™ if blood pressure rises significantly. (<a href="#ID_6c2f745d-41d5-4a3e-9622-7094e69cbac7">5.3</a>)</dd>
<dt>•</dt>
<dd>Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Tri-Estarylla™. Consider an alternate contraceptive method for women with uncontrolled <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. (<a href="#ID_b53044a8-8ff0-4fce-86e2-fbda5e76133a">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: Evaluate significant change in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and discontinue Tri-Estarylla™ if indicated. (<a href="#ID_522d802f-fb0e-4751-9479-405f90d1561e">5.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>: Evaluate irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. (<a href="#ID_2b3212a1-069e-4552-8496-ea295921d660">5.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions reported during clinical trials (≥2%) were: </p>
<p class="Highlighta">Tri-Estarylla™: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, abdominal/<span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">genital discharge</span>, breast issues (including <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, discharge, and enlargement), mood disorders (including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood altered</span>), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#ID_40129fe4-8c48-4aef-89b4-5c9145619506">6.1</a>) </p>
<p class="Highlighta">Tri-Estarylla™: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, breast issues (including <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, enlargement, and discharge), <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, abdominal/<span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, mood disorders (including mood alteration and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>), <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">genital discharge</span>, changes in weight (including <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> or decreased). (<a href="#ID_40129fe4-8c48-4aef-89b4-5c9145619506">6.1</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz, Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Drugs or herbal products that induce certain enzymes including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs. (<a href="#ID_d96028c3-b509-41c5-8d82-8ddb838cbf7f">7.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing mothers: Not recommended; can decrease milk production. (<a href="#ID_47e5d169-096a-42cf-b978-b50d05e93b0f">8.3</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Oral Contraceptive</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 How to Start Tri-Estarylla™ </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 How to Take Tri-Estarylla™</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Missed Tablets</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Advice in Case of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disturbances</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Tri-Estarylla™ Use for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Thromboembolic Disorders and Other Vascular Problems</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Disease</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 High Blood Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Carbohydrate and Lipid Metabolic Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	COC Use Before or During Early Pregnancy</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Carcinoma of Breast and Cervix</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Effect on Binding Globulins</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Monitoring</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effects of Other Drugs on Combined Oral Contraceptives</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effects of Combined Oral Contraceptives on Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Interference with Laboratory Tests</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Contraception</a></h2>
<h2><a href="#section-13.2" class="toc">14. 2 <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage Conditions</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_bafc2d00-a09b-45c3-b1aa-a82f4ba73e07"></a><a name="section-1"></a><p></p>
<h1>WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS<span class="Bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years  of  age,  and  with  the  number  of  cigarettes  smoked.  For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS (4)].</span>
</h1>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_7e9c8a4d-7cb1-4d4a-a838-da0afaf96822"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b9dcdd9c-1345-4054-a07a-3fc4a73843fe"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Oral Contraceptive</h2>
<p class="First">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP) is indicated for use by females of reproductive potential to prevent pregnancy [see <span class="Bold"><a href="#ID_030d655e-9f4b-4162-a3c3-f037f84cd08d">CLINICAL STUDIES (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bc789972-cef7-4fd9-bb1f-40be635366f8"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></h2>
<p class="First">Tri-Estarylla™ is indicated for the treatment of moderate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>. Tri-Estarylla™ should be used for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> only if the patient desires an oral contraceptive for birth control [see <span class="Bold">CLINICAL STUDIES (<a href="#ID_030d655e-9f4b-4162-a3c3-f037f84cd08d">14</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_e4be4f2a-3e17-4a83-abd4-581f4f460d9f"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0a22a8eb-0627-4871-a14c-077c5d0bfc92"></a><a name="section-2.1"></a><p></p>
<h2>2.1 How to Start Tri-Estarylla™ </h2>
<p class="First">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP), is dispensed in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack [see <span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING (<a href="#ID_3c0fa487-dafd-4a84-8d64-077ab7c7c946">16</a>)].</span> Tri-Estarylla™ may be started using either a Day 1 start or a Sunday start (see <span class="Bold">Table 1).</span>  For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a647c8d9-7db4-4413-a452-bd61b24e6c86"></a><a name="section-2.2"></a><p></p>
<h2>2.2 How to Take Tri-Estarylla™</h2>
<p class="First"><span class="Bold">Table 1: Instructions for Administration of Tri-Estarylla™</span></p>
<table>
<col width="58%">
<col width="58%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top"><span class="Bold">Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling.</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">
<p class="First"><span class="Bold">Starting COCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start)</span></p>
<p><br><span class="Bold">Important</span><span class="Bold">:</span><br>Consider the possibility of ovulation and conception prior to initiation of this product.</p>
<p><br><span class="Bold">Tablet Color:</span><br></p>
<dl>
<dt>•</dt>
<dd>Tri-Estarylla™ active tablets are white (Day 1 to Day 7), light blue (Day 8 to Day 14) and blue (Day15 to Day 21).</dd>
<dt>•</dt>
<dd>Tri-Estarylla™ has green inactive tablets (Day 22 to Day 28).</dd>
</dl>
</td>
<td class="Botrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Day 1 Start:</span><br></p>
<dl>
<dt>•</dt>
<dd>Take first active tablet without regard to meals on the first day of menses.</dd>
<dt>•</dt>
<dd>Take subsequent active tablets once daily at the same time each day for a total of 21 days.</dd>
<dt>•</dt>
<dd>Take one <span class="Bold">green</span> inactive tablet daily for 7 days and at the same time of day that active tablets were taken.</dd>
<dt>•</dt>
<dd>Begin each subsequent <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack on the same day of Tri-Estarylla™ the week as the first cycle <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack (i.e., on the day after taking the last inactive tablet)</dd>
</dl>
</td>
</tr>
<tr><td class="Botrule Rrule" valign="top">
<p class="First"><span class="Bold">Sunday Start:</span><br></p>
<dl>
<dt>•</dt>
<dd>Take first active tablet without regard to meals on the first Sunday after the onset of menses. <span class="Bold">Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of Tri-Estarylla™.</span>
</dd>
<dt>•</dt>
<dd>Take subsequent active tablets once daily at the same time each day for a total of 21 days.</dd>
<dt>•</dt>
<dd>Take one <span class="Bold">green </span>inactive tablet daily for the following 7 days and at the same time of day that active tablets were taken.</dd>
<dt>•</dt>
<dd>Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed.</dd>
</dl>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Switching to Tri-Estarylla™ from another oral contraceptive </span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><p class="First">Start on the same day that a new pack of the previous oral contraceptive would have started.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Switching from another contraceptive method to Tri-Estarylla™</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Start Tri-Estarylla™:</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Transdermal patch</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>On the day when next application would have been scheduled</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Vaginal ring</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>On the day when next insertion would have been scheduled</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Injection</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>On the day when next injection would have been scheduled</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Intrauterine contraceptive</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>On the day of removal</dd>
<dt>•</dt>
<dd>If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle  pack.</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd><span class="Bold">Implant</span></dd>
</dl></td>
<td class="Botrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>On the day of removal</dd>
</dl></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="Underline">Starting Tri-</span>Estarylla™ <span class="Underline">after Abortion or <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Miscarriage</span></span></span></span></p>
<p><span class="Bold"><span class="Italics">First-trimester</span></span></p>
<dl>
<dt>•</dt>
<dd>After a first-trimester abortion or <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, Tri-Estarylla™ may be started immediately. An additional method of contraception is not needed if Tri-Estarylla™ is started immediately.</dd>
<dt>•</dt>
<dd>If Tri-Estarylla™ is not started within 5 days after termination of the pregnancy, the patient should use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of her first cycle <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of Tri-Estarylla™.</dd>
</dl>
<p><span class="Bold"><span class="Italics">Second-trimester</span></span></p>
<dl>
<dt>•</dt>
<dd>Do not start until 4 weeks after a second-trimester abortion or <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, due to the increased risk of thromboembolic disease. Start Tri-Estarylla™, following the instructions in Table 1 for Day 1 or Sunday start, as desired. If using Sunday start, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of Tri-Estarylla™. [See <a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>, <a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>, and <a href="#_Ref">FDA-Approved Patient Labeling</a>.]</dd>
</dl>
<p><span class="Bold"><span class="Italics">Starting Tri-Estarylla™ after Childbirth</span></span></p>
<dl>
<dt>•</dt>
<dd>Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with Tri-Estarylla™ following the instructions in Table 1 (above) for women not currently using hormonal contraception.</dd>
<dt>•</dt>
<dd>Tri-Estarylla™ is not recommended for use in lactating women [see <span class="Bold"><a href="#ID_47e5d169-096a-42cf-b978-b50d05e93b0f">USE IN SPECIFIC POPULATIONS (8.3)</a>].</span>
</dd>
<dt>•</dt>
<dd>If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of Tri-Estarylla™. [See <span class="Bold"><a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>, <a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>, <a href="#_Ref">USE IN SPECIFIC POPULATIONS (8.1</a> and <a href="#ID_47e5d169-096a-42cf-b978-b50d05e93b0f">8.3)</a>, and <a href="#_Ref">FDA-Approved Patient Labeling</a></span>].</dd>
</dl>
<p><span class="Bold">BEFORE YOU START TAKING YOUR PILLS</span></p>
<dl>
<dt></dt>
<dd><dl>
<dt>1.</dt>
<dd>
<span class="Bold">DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.</span><br>It is important to take it at about the same time every day.</dd>
<dt>2.</dt>
<dd><span class="Bold">LOOK AT YOUR PILL  <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</span></dd>
</dl></dd>
</dl>
<p>The pill pack has 21 "active" pills (with hormones) to take for 3 weeks. This is followed by 1 week of "reminder" green pills (without hormones).</p>
<p></p>
<p>3.ALSO FIND:</p>
<dl>
<dt></dt>
<dd><dl>
<dt></dt>
<dd><dl>
<dt>1)</dt>
<dd>where on the pack to start taking pills,</dd>
<dt>2)</dt>
<dd>in what order to take the pills (follow the arrows)</dd>
<dt>3)</dt>
<dd>The week numbers as shown in the diagram below</dd>
</dl></dd>
</dl></dd>
</dl>
<div class="Figure">
<a name="ID0ENDEK"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-01.jpg">
</div>
<p>4.BE SURE YOU HAVE READY AT ALL TIMES:</p>
<dl>
<dt> </dt>
<dd>Another kind of birth control (such as a condom or spermicide) to use as a back-up method in case you miss pills.</dd>
<dt> </dt>
<dd>An extra, full pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3e699fa9-0214-4d78-8ef9-3da60146738d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Missed Tablets</h2>
<table>
<caption><span>Table 2: Instructions for Missed Tri-Estarylla™ Tablets</span></caption>
<col width="43%">
<col width="44%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">If one active tablet is missed in Weeks 1, 2, or 3</span></p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Take the tablet as soon as possible. Continue taking one tablet a day until the pack is finished.</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">If two active tablets are missed in Week 1 or Week 2</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Take the two missed tablets as soon as possible and the next two active tablets the next day. Continue taking one tablet a day until the pack is finished. Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets.</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">If two active tablets are missed in the third week or three or more active tablets are missed in a row in Weeks 1, 2, or 3</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Day 1 start: Throw out the rest of the pack and start a new pack that same day.</span><br><span class="Bold">Sunday start: Continue taking one tablet a day until Sunday, then throw out the rest of the pack and start a new pack that same day. Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets.</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0480d090-d843-4106-84cc-716649a52522"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Advice in Case of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disturbances</span></h2>
<p class="First">In case of severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, absorption may not be complete and additional contraceptive measures should be taken. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs within 3 to 4 hours after taking an active tablet, handle this as a missed tablet [see <span class="Bold"><a href="#_Ref">FDA-Approved Patient Labeling</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6789e216-d01a-4b10-ab4c-fc3313d906c8"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Tri-Estarylla™ Use for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></h2>
<p class="First">The timing of initiation of dosing with Tri-Estarylla™ for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> should follow the guidelines for use of Tri-Estarylla™ as an oral contraceptive. Consult the <span class="Bold">DOSAGE AND ADMINISTRATION section (2.1)</span> for instructions</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_54cd9a6c-4832-440e-8dbc-1b18abaab03a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tri-Estarylla™ Tablets are available in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards. Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack contains</p>
<p>28 tablets in the following order:</p>
<dl>
<dt>•</dt>
<dd>7 white (active) tablets are round, debossed with SZ on one side and T2 on the other side and contains 0.18 mg of norgestimate and 0.035 mg of ethinyl estradiol.</dd>
<dt>•</dt>
<dd>7 light blue (active) tablets are round, debossed with SZ on one side and T3 on the other side and contains 0.215 mg of norgestimate and 0.035 mg of ethinyl estradiol.</dd>
<dt>•</dt>
<dd>7 blue (active) tablets are round, debossed with SZ on one side and T4 on the other side and contains 0.25 mg of norgestimate and 0.035 mg of ethinyl estradiol.</dd>
<dt>•</dt>
<dd>7 green (inert) tablets are round, debossed with SZ on one side and J1 on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_24b63b06-0ffa-496f-8469-d025be784908"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Do not prescribe Tri-Estarylla™ to women who are known to have the following conditions:</p>
<dl>
<dt>•</dt>
<dd>A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:</dd>
<dt>•</dt>
<dd>Smoke, if over age 35 [see <span class="Bold"><a href="#ID_bafc2d00-a09b-45c3-b1aa-a82f4ba73e07">BOXED WARNING</a> and <a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, now or in the past [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have inherited or acquired hypercoagulopathies [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have cerebrovascular disease [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, <span class="product-label-link" type="condition" conceptid="4249899" conceptname="Subacute bacterial endocarditis">subacute bacterial endocarditis</span> with valvular disease, or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>) [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> [see <span class="Bold"><a href="#ID_6c2f745d-41d5-4a3e-9622-7094e69cbac7">WARNINGS AND PRECAUTIONS (5.3)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus with vascular disease [see <span class="Bold"><a href="#ID_b53044a8-8ff0-4fce-86e2-fbda5e76133a">WARNINGS AND PRECAUTIONS (5.5)</a>]</span>
</dd>
<dt>•</dt>
<dd>Have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> with focal neurological symptoms or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> [see <span class="Bold"><a href="#ID_522d802f-fb0e-4751-9479-405f90d1561e">WARNINGS AND PRECAUTIONS (5.6)</a>]</span><dl>
<dt>1.</dt>
<dd>Women over age 35 with any <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> [see <span class="Bold"><a href="#ID_522d802f-fb0e-4751-9479-405f90d1561e">WARNINGS AND PRECAUTIONS (5.6)</a>]</span>
</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, benign or malignant, or liver disease [see <span class="Bold"><a href="#ID_49d51c87-7f56-447b-b452-d5828da3cc15">WARNINGS AND PRECAUTIONS (5.2)</a>]</span>
</dd>
<dt>•</dt>
<dd>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> [see <span class="Bold"><a href="#ID_2b3212a1-069e-4552-8496-ea295921d660">WARNINGS AND PRECAUTIONS (5.7)</a>]</span>
</dd>
<dt>•</dt>
<dd>Pregnancy, because there is no reason to use COCs during pregnancy [see <span class="Bold"><a href="#ID_2de866ff-010f-46ac-a02f-3ce4c0912073">WARNINGS AND PRECAUTIONS (5.8)</a> and <a href="#_Ref">USE IN SPECIFIC POPULATIONS (8.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past [see <span class="Bold"><a href="#ID_fcad960f-d784-4461-8e75-9117cd5e60b1">WARNINGS AND PRECAUTIONS (5.10)</a>]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_60dda5a8-f4e2-42bd-8da8-1e04e4523211"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7cb77152-73d2-492c-b932-23b6ac4989ec"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Thromboembolic Disorders and Other Vascular Problems</h2>
<dl>
<dt>•</dt>
<dd>Stop Tri-Estarylla™ if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.</dd>
<dt>•</dt>
<dd>Stop Tri-Estarylla™ if there is unexplained <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, or retinal vascular lesions. Evaluate for <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span> immediately [see <a href="#ID_9eb84112-d770-425c-994f-16cab065be73">ADVERSE REACTIONS (6.2)</a>].</dd>
<dt>•</dt>
<dd>If feasible, stop Tri-Estarylla™ at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.</dd>
<dt>•</dt>
<dd>Start Tri-Estarylla™ no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.</dd>
<dt>•</dt>
<dd>The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.</dd>
<dt>•</dt>
<dd>Use of COCs also increases the risk of arterial thromboses such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>). This risk increases with age, particularly in women over 35 years of age who smoke.</dd>
<dt>•</dt>
<dd>Use COCs with caution in women with cardiovascular disease risk factors.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49d51c87-7f56-447b-b452-d5828da3cc15"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Disease</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired Liver Function</span></span></span></p>
<p>Do not use Tri-Estarylla™ in women with liver disease, such as acute <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> or severe (decompensated) <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">cirrhosis of liver</span> [see <span class="Bold"><a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>]. </span>Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Tri-Estarylla™ if <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver Tumors</span></span></span></p>
<p>Tri-Estarylla™ is contraindicated in women with benign and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> [see <span class="Bold"><a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>]</span>. <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt;8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6c2f745d-41d5-4a3e-9622-7094e69cbac7"></a><a name="section-5.3"></a><p></p>
<h2>5.3 High Blood Pressure</h2>
<p class="First">Tri-Estarylla™ is contraindicated in women with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with vascular disease [see <span class="Bold"><a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>].</span> For women with well-controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, monitor blood pressure and stop Tri-Estarylla™ if blood pressure rises significantly.</p>
<p>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing concentrations of progestin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5b761eab-f40c-4301-bce9-3326c39d8ad2"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">Studies suggest a small increased relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among COC users. Use of COCs may worsen existing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>. A past history of COC-related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> may be at an increased risk for COC related <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b53044a8-8ff0-4fce-86e2-fbda5e76133a"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Carbohydrate and Lipid Metabolic Effects</h2>
<p class="First">Carefully monitor prediabetic and diabetic women who take Tri-Estarylla™. COCs may decrease glucose tolerance.</p>
<p>Consider alternative contraception for women with uncontrolled <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. A small proportion of women will have adverse lipid changes while on COCs.</p>
<p>Women with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, or a family history thereof, may be at an increased risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> when using COCs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_522d802f-fb0e-4751-9479-405f90d1561e"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">If a woman taking Tri-Estarylla™ develops new <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that are recurrent, persistent, or severe, evaluate the cause and discontinue Tri-Estarylla™ if indicated.</p>
<p>Consider discontinuation of Tri-Estarylla™ in the case of increased frequency or severity of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> during COC use (which may be prodromal of a cerebrovascular event).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2b3212a1-069e-4552-8496-ea295921d660"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></h2>
<p class="First"><span class="Bold"><span class="Italics">Unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and Spotting</span></span></p>
<p>Unscheduled (breakthrough or intracyclic) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting sometimes occur in patients on COCs, especially during the first three months of use. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> irregularities may resolve over time or with a change to a different contraceptive product.</p>
<p>In clinical trials of Tri-Estarylla™, the frequency and duration of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or spotting was assessed in 1,647 patients (21,275 evaluable cycles) and 4,826 patients (35,546 evaluable cycles), respectively. A total of 231 (4.8%) women discontinued Tri-Estarylla™ at least in part, due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting. Based on data from the clinical trials, 13 to 38% of women using Tri-Estarylla™ experienced unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> per cycle in the first year. The percent of women who experienced breakthrough/unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tended to decrease over time.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> and <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">Oligomenorrhea</span></span></span></p>
<p>Women who use Tri-Estarylla™ may experience <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. Some women may experience <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span> after discontinuation of COCs, especially when such a condition was pre-existent.</p>
<p>If scheduled (withdrawal) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2de866ff-010f-46ac-a02f-3ce4c0912073"></a><a name="section-5.8"></a><p></p>
<h2>5.8	COC Use Before or During Early Pregnancy</h2>
<p class="First">Extensive epidemiological studies have revealed no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span> are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue Tri-Estarylla™ use if pregnancy is confirmed.</p>
<p>Administration of COCs to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy [see <span class="Bold"><a href="#_Ref">USE IN SPECIFIC POPULATIONS (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3cf4db4d-1ed7-459a-91e1-64a3ffd6bda8"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Carefully observe women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and discontinue Tri-Estarylla™ if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fcad960f-d784-4461-8e75-9117cd5e60b1"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Carcinoma of Breast and Cervix</h2>
<dl>
<dt>•</dt>
<dd>Tri-Estarylla™ is contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally sensitive [see <a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a>].</dd>
</dl>
<p class="First">There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.</p>
<dl>
<dt>•</dt>
<dd>Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47188e72-8ef2-45a2-b739-ca304094ce62"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Effect on Binding Globulins</h2>
<p class="First">The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3ac0eeb6-b67a-4104-8bb0-34e05ab0f3be"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Monitoring</h2>
<p class="First">A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4ea9a53a-b11a-43e0-a9e6-ab6b366d8a95"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></h2>
<p class="First">In women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>, exogenous estrogens may induce or exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7bf3ebf4-d342-461d-bbe0-18f5a02775c4"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> may occasionally occur, especially in women with a history of <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span> gravidarum. Women with a tendency to <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span> should avoid exposure to the sun or ultraviolet radiation while taking Tri-Estarylla™.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_c847869a-1d19-4f39-9906-3ca7cf354075"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:</p>
<dl>
<dt>•</dt>
<dd>Serious cardiovascular events and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [see <span class="Bold"><a href="#ID_bafc2d00-a09b-45c3-b1aa-a82f4ba73e07">BOXED WARNING</a> and <a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Vascular events [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd>Liver disease [see <span class="Bold"><a href="#ID_49d51c87-7f56-447b-b452-d5828da3cc15">WARNINGS AND PRECAUTIONS (5.2)</a>]</span>
</dd>
<dt>•</dt>
<dd>Adverse reactions commonly reported by COC users are:</dd>
<dt>•</dt>
<dd>Irregular <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">Breast tenderness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_40129fe4-8c48-4aef-89b4-5c9145619506"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of Tri-Estarylla™ was evaluated in 4,826 healthy women of child-bearing potential   who   participated   in   6   clinical   trials   and   received   at   least   1   dose   of Tri-Estarylla™ for contraception. Two trials were randomized active-controlled trials and 4 were uncontrolled open-label trials. In 3 trials, subjects were followed for up to 24 cycles; in 2 trials, subjects were followed for up to 12 cycles; and in 1 trial, subjects were followed for up to 6 cycles.</p>
<p><span class="Bold"><span class="Italics">Common Adverse Reactions (≥ 2% of subjects): </span></span>The most common adverse reactions reported by at least 2% of the 4,826 women were the following in order of decreasing incidence: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (33.6%), breast issues (including <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, enlargement, and discharge) (8%), <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span> (7.1%), abdominal/<span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span> (5.6%), mood disorders (including mood alteration and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) (3.8%), <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">genital discharge</span> (3.2%), and changes in weight (including <span class="product-label-link" type="condition" conceptid="4093974" conceptname="Weight fluctuates">weight fluctuation</span>, increased or decreased) (2.5%).</p>
<p><span class="Bold"><span class="Italics">Adverse Reactions Leading to Study Discontinuation: </span></span>Over the trials, between 9 to 27% of subjects discontinued the trial due to an adverse reaction.   The most common adverse reactions (≥1%) leading to discontinuation were: <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span> (4.3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (2.4%), mood disorders (including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood altered</span>) (1.1%), and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> (1.1%).</p>
<p><span class="Bold"><span class="Italics">Serious Adverse Reactions: </span></span> breast cancer (1 subject), carcinoma of the cervix in situ (1 subject), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (1 subject), and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (2 subjects).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9eb84112-d770-425c-994f-16cab065be73"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse drug reactions have been reported from worldwide postmarketing experience with norgestimate/ ethinyl estradiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>:</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>;</p>
<p><span class="Bold"><span class="Italics">Neoplasms Benign, Malignant and Unspecified (Incl. <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">Polyps</span>)</span>:</span> Breast cancer, benign breast neoplasm, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenoma</span>, <span class="product-label-link" type="condition" conceptid="4047301" conceptname="Focal nodular hyperplasia">focal nodular hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="78473" conceptname="Solitary cyst of breast">breast cyst</span>;</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>;</p>
<p><span class="Bold"><span class="Italics">Metabolism and Nutrition Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>;</p>
<p><span class="Bold"><span class="Italics">Psychiatric Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>;</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>;</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Visual impairment</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="4012868" conceptname="Contact lens intolerance">contact lens intolerance</span>;</p>
<p><span class="Bold"><span class="Italics">Ear and Labyrinth Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>;</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>;</p>
<p><span class="Bold"><span class="Italics">Vascular Events</span>:</span> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>;</p>
<p><span class="Bold"><span class="Italics">Arterial Events:</span></span> Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>;</p>
<p><span class="Bold"><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>;</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>;</p>
<p><span class="Bold"><span class="Italics">Hepatobiliary Disorders</span></span><span class="Bold"><span class="Italics">:</span></span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>;</p>
<p><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>;</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>;</p>
<p><span class="Bold"><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">Ovarian cyst</span>, <span class="product-label-link" type="condition" conceptid="79098" conceptname="Suppressed lactation">suppressed lactation</span>, <span class="product-label-link" type="condition" conceptid="4243181" conceptname="Vulvovaginal dryness">vulvovaginal dryness</span>;</p>
<p><span class="Bold"><span class="Italics">General Disorders and Administration Site Conditions</span>:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, asthenic conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_05b1bcfb-a50c-486b-a2f6-f5c007e8866e"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.</p>
<p>No drug-drug interaction studies were conducted with Tri-Estarylla™.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d96028c3-b509-41c5-8d82-8ddb838cbf7f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effects of Other Drugs on Combined Oral Contraceptives</h2>
<p class="First"><span class="Bold"><span class="Italics">Substances decreasing the plasma concentrations of COCs</span></span></p>
<p>Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.</p>
<p><span class="Bold"><span class="Italics">Colesevelam:</span></span> Colesevelam, a bile acid sequestrant, given together with a COC, has been shown to significantly decrease the AUC of EE. The drug interaction between the contraceptive and colesevelam was decreased when the two drug products were given 4 hours apart.</p>
<p><span class="Bold"><span class="Italics">Substances increasing the plasma concentrations of COCs</span></span></p>
<p>Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.</p>
<p><span class="Bold"><span class="Italics">Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV)/<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors</span></span></p>
<p>Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4014fd78-34a1-4cb2-a5fc-3f2f4ce508a5"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effects of Combined Oral Contraceptives on Other Drugs</h2>
<dl>
<dt>•</dt>
<dd>COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations.</dd>
<dt>•</dt>
<dd>COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments of lamotrigine may be necessary.</dd>
</dl>
<p class="First">Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_52134a44-ea3e-44f0-bd39-432746fac3a3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Interference with Laboratory Tests</h2>
<p class="First">The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_4d85789e-b7e5-4567-bdba-1e3d5172b26b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_a10b3377-a7f5-4ccf-921a-373d00667c09"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">There is little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (including cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span>) following exposure to low dose COCs prior to conception or during early pregnancy.</p>
<p>Do not administer COCs to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> as a test for pregnancy. Do not use COCs during pregnancy to treat threatened or habitual abortion.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_47e5d169-096a-42cf-b978-b50d05e93b0f"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_b666cf1f-9cb9-4238-8000-1c26ee36df5e"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of Tri-Estarylla™ have been established in women of reproductive age. Efficacy is expected to be the same for post-pubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
<p>There was no significant difference between Tri-Estarylla™ tablets and placebo in mean change in total lumbar spine (L1-L4) and total hip bone mineral density between baseline and   Cycle   13   in   123   adolescent   females   with   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>   nervosa   in   a   double-blind, placebo-controlled, multicenter, one-year treatment duration clinical trial for the Intent To Treat (ITT) population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_68dccc73-5757-44ee-b227-aa2756615c08"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Tri-Estarylla™ has not been studied in postmenopausal women and are not indicated in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9246dd04-7310-4c38-a44e-b21448640145"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of Tri-Estarylla™ has not been studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. However, steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. [See <span class="Bold"><a href="#ID_24b63b06-0ffa-496f-8469-d025be784908">CONTRAINDICATIONS (4)</a> and <a href="#ID_49d51c87-7f56-447b-b452-d5828da3cc15">WARNINGS AND PRECAUTIONS (5.2)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_53682ef9-33d6-4365-bf50-b12e5c0763b4"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The pharmacokinetics of Tri-Estarylla™ has not been studied in women with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_1e24cc36-8ba8-446b-b975-7d093b3df66f"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_1ea53b74-e9c9-4679-810a-ac5d5110cf0a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Each of the following products is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and ethinyl estradiol is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).</p>
<dl>
<dt>•</dt>
<dd>Each active white tablet contains 0.18 mg norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include crospovidone, lactose anhydrous, magnesium stearate, and pregelatinized starch.</dd>
<dt>•</dt>
<dd>Each active light blue tablet contains 0.215 mg norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include crospovidone, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch</dd>
<dt>•</dt>
<dd>Each active blue tablet contains 0.25 mg norgestimate and 0.035 mg of ethinyl estradiol. Inactive ingredients include crospovidone, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch</dd>
<dt>•</dt>
<dd>Each  green tablet contains only inert ingredients, as follows: crospovidone, D &amp;C Yellow No.10 aluminum Lake, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch</dd>
</dl>
<div class="Figure">
<a name="ID0EBDDM"></a><img alt="Chemical Structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-02.jpg">
</div>
<div class="Figure">
<a name="ID0EHFDM"></a><img alt="Chemical Structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_01074a76-d904-41ef-b453-6c7e205110d9"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_77452f2a-b211-4b02-b614-873f9e66e21a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Oral Contraception</span><p class="First">COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.</p>
</dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></span></dd>
</dl>
<p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of ethinyl estradiol and norgestimate increases sex hormone-binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in otherwise healthy women with this skin condition has not been established.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_b1bb1db6-7d0f-4ec4-a635-fd76754ba0be"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">No specific pharmacodynamic studies were conducted with norgestimate and ethinyl estradiol.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0d014898-d888-479f-ae45-11c4a0075fb8"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Norgestimate (NGM) and EE are rapidly absorbed following oral administration. NGM is rapidly and completely metabolized by first pass (intestinal and/or hepatic) mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active metabolites of norgestimate.</p>
<p>Peak serum concentrations of NGMN and EE are generally reached by 2 hours after administration of norgestimate/ ethinyl estradiol. Accumulation following multiple dosing of the 250 mcg NGM / 35 mcg EE dose is approximately 2-fold for NGMN and EE compared with single dose administration. The pharmacokinetics of NGMN is dose-proportional following NGM doses of 180 mcg to 250 mcg. Steady-state concentration of EE is achieved by Day 7 of each dosing cycle. Steady-state concentrations of NGMN and NG are achieved by Day 21. Non-linear accumulation (approximately 8 fold) of NG is observed as a result of high-affinity binding to SHBG, which limits its biological activity <span class="Bold">(Table 3).</span></p>
<a name="_Reftable3"></a><table>
<caption><span>Table 3:  Summary of NGMN, NG and EE pharmacokinetic parameters.</span></caption>
<col width="10%">
<col width="8%">
<col width="7%">
<col width="14%">
<col width="13%">
<col width="18%">
<col width="23%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="7" valign="top">C<span class="Sub">max</span> = peak serum concentration, t<span class="Sub">max</span> = time to reach peak serum concentration, AUC<span class="Sub">0–24h</span> = area under serum concentration vs time curve from 0 to 24 hours, t<span class="Sub">1/2</span> = elimination half-life, NC = not calculated.</td></tr>
<tr><td class="Botrule" align="left" colspan="7" valign="top">NGMN and NG: C<span class="Sub">max</span> = ng/mL, AUC<span class="Sub">0–24h </span>= h∙ng/mL</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="7" valign="top">EE: C<span class="Sub">max</span>= pg/mL, AUC<span class="Sub">0–24h </span>= h∙pg/mL</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First"><span class="Bold">Mean (SD) Pharmacokinetic Parameters of Norgestimate and Ethinyl Estradiol During a Three Cycle Study</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Analyte</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Cycle</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Day</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">t<span class="Sub">max</span> (h)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">0-24h</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">t<span class="Sub">1/2</span>(h)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">NGMN</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.80 (0.46)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.42 (0.73)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15 (3.88)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.12 (0.56)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.21 (0.26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.1 (4.97)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.66 (0.47)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.29 (0.26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21.4 (3.46)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22.3 (6.54)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">NG</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.94 (0.82)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.15 (4.05)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">34.8 (16.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (1.04)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.21 (2.03)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">55.2 (23.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.66 (1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.58 (2.97)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">69.3 (23.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">40.2 (15.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">EE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">124 (39.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.27 (0.26)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1130 (420)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">128 (38.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.32 (0.25)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1130 (324)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NC</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">126 (34.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.31 (0.56)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1090 (359)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15.9 (4.39)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Food Effect</span></span></p>
<p>The effect of food on the pharmacokinetics of norgestimate and ethinyl estradiol has not been studied.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>NGMN and NG are highly bound (&gt;97%) to serum proteins. NGMN is bound to albumin and not to SHBG, while NG is bound primarily to SHBG. EE is extensively bound (&gt;97%) to serum albumin and induces an increase in the serum concentrations of SHBG.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>NGM is extensively metabolized by first-pass mechanisms in the gastrointestinal tract and/or liver. NGM's primary active metabolite is NGMN. Subsequent hepatic metabolism of NGMN occurs and metabolites include NG, which is also active, and various hydroxylated and conjugated metabolites. Although NGMN and its metabolites inhibit a variety of P450 enzymes in human liver microsomes, under the recommended dosing regimen, the <span class="Italics">in vivo</span> concentrations of NGMN and its metabolites, even at the peak serum levels, are relatively low compared to the inhibitory constant (K<span class="Sub">i</span>). EE is also metabolized to various hydroxylated products and their glucuronide and sulfate conjugates.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>The metabolites of NGMN and EE are eliminated by renal and fecal pathways. Following administration of <span class="Sup">14</span>C-norgestimate, 47% (45 to 49%) and 37% (16 to 49%) of the administered radioactivity was eliminated in the urine and feces, respectively. Unchanged NGM was not detected in the urine. In addition to 17-deacetyl norgestimate, a number of metabolites of NGM have been identified in human urine following administration of radiolabeled NGM. These include 18, 19-Dinor-17-pregn-4-en-20-yn-3-one,17-hydroxy-13-ethyl,(17α)-(-);18,19-Dinor-5β-17-pregnan-20-yn,3α,17β-dihydroxy-13-ethyl,(17α), various hydroxylated metabolites and conjugates of these metabolites.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_44187438-56b0-4c37-b738-386152101501"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_191d6284-9a98-46ab-8d55-31792fc5be20"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">[See <span class="Bold"><a href="#ID_49d51c87-7f56-447b-b452-d5828da3cc15">WARNINGS AND PRECAUTIONS (5.2</a>, <a href="#ID_fcad960f-d784-4461-8e75-9117cd5e60b1">5.10)</a></span> and <span class="Bold"><a href="#_Ref">USE IN SPECIFIC POPULATIONS (8.1)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_030d655e-9f4b-4162-a3c3-f037f84cd08d"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bed8f500-af5a-4871-82b1-0a245847c115"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Contraception</h2>
<p class="First">In three US clinical trials with norgestimate and ethinyl estradiol, 1,651 women aged 18 to 38 years were studied for up to 24 cycles, proving a total of 24,272 cycles of exposure. The racial demographic was about 73 to 86% Caucasian, 8 to 13% African-American, 6 to 14% Hispanic with the remainder Asian or Other (≤1%). There were no exclusions on the basis of weight; the weight range for women treated was 82 to 303 lbs, with a mean weight of about 135 lbs. The pregnancy rate was approximately 1 pregnancy per 100 women-years.</p>
<p>In four clinical trials with norgestimate and ethinyl estradiol, 4,756 women aged 15 to 41 years were studied for 24 cycles, providing a total of 45,244 cycles of exposure. The racial demographic was about 87 to 90% Caucasian, 6 to 10% African-American, with the remainder Asian (≤1%) or Other (2 to 5%).  There were no exclusions on the basis of weight; the weight range for women treated was 80-310 lbs, with a mean weight of about 132 lbs.  The pregnancy rate was approximately 1 pregnancy per 100 women-years.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bed6056b-e972-44fa-8d9a-c6173c652b09"></a><a name="section-13.2"></a><p></p>
<h2>14. 2 <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></h2>
<p class="First">Norgestimate and ethinyl estradiol was evaluated for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in two randomized, double-blind, placebo-controlled, multicenter, six- (28 day) cycle studies. Two hundred twenty- one patients received Tri-norgestimate and ethinyl estradiol and 234 patients received placebo. Mean age at enrollment for both groups was 28 years. At the end of 6 months, the mean total lesion count changed from 55 to 31 (42% reduction) in patients treated with norgestimate and ethinyl estradiol and from 54 to 38 (27% reduction) in patients similarly treated with placebo. <span class="Bold">Table 4</span> summarizes the changes in lesion count for each type of lesion. Based on the investigator’s global assessment conducted at the final visit, patients treated with norgestimate and ethinyl estradiol showed a statistically significant improvement in total lesions compared to those treated with placebo.</p>
<a name="_RefID0ETPBG"></a><table>
<caption><span>Table 4: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne Vulgaris</span> Indication. Combined Results: Two Multicenter, Placebo-Controlled Trials.  Observed Means at Six Months (LOCF)* and at Baseline. Intent-to-Treat Population. </span></caption>
<col width="22%">
<col width="12%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Tri-Estarylla™</span></p>
<p><span class="Bold">(N=221)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(N=234)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Difference in Counts</span></p>
<p><span class="Bold">Between Tri-Estarylla™</span></p>
<p><span class="Bold">and Placebo at</span></p>
<p><span class="Bold">6 Months</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"># of Lesions</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Counts</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">% Reduction</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Counts</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">% Reduction</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Bold">INFLAMMATORY LESIONS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">48%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">30%</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sixth Month Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (95% CI: -1.2, 5.1)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Bold">NON­INFLAMMATORY LESIONS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">34%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">21%</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sixth Month Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (95% CI: -0.2, 7.8)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Bold">TOTAL LESIONS</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">55</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">42%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7 (95% CI: 2.0, 11.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sixth Month Mean</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">38</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
</tbody>
</table>
<p>*LOCF: Last Observation Carried Forward</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_3c0fa487-dafd-4a84-8d64-077ab7c7c946"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0574f194-8913-4f8f-ac45-b57f8c57eccc"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Bold">Tri-Estarylla<span class="Sup">TM</span></span> (norgestimate and ethinyl estradiol tablets, USP) is available in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> containing 28 tablets as follows:</p>
<p>Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains 21 active tablets and 7 inactive tablets. </p>
<p>7 white (active) tablets are round, debossed with SZ on one side and T2 on the other side and contains 0.18 mg of  norgestimate and 0.035 mg of ethinyl estradiol .</p>
<p>7 light blue (active) tablets are round, debossed with SZ on one side and T3 on the other side and contains 0.215 mg of  norgestimate and 0.035 mg of ethinyl estradiol .</p>
<p>7 blue (active) tablets are round, debossed with SZ on one side and T4 on the other side and contains 0.25 mg of  norgestimate and 0.035 mg of ethinyl estradiol .</p>
<p>7 green (inert) tablets are round, debossed with SZ on one side and J1 on the other side.</p>
<dl>
<dt> </dt>
<dd>NDC 0781-4060-15, one box containing 3 individual unit cartons</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4c4b63d6-6818-41c6-9d2a-822aa733e55e"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage Conditions</h2>
<dl>
<dt>•</dt>
<dd>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</dd>
<dt>•</dt>
<dd>Protect from light.</dd>
</dl>
<p class="First">Keep out of reach of children</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_e4ef0153-2952-4c8e-965a-e9c5f955bb4a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold"><span class="Italics">See FDA-approved patient labeling (<a href="#_Ref">Patient Information</a> and <a href="#_Ref">Instructions for Use</a>).</span></span></p>
<p>Counsel patients about the following information:</p>
<dl>
<dt>•</dt>
<dd>Cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs [see <span class="Bold"><a href="#ID_bafc2d00-a09b-45c3-b1aa-a82f4ba73e07">Boxed Warning</a>]</span>.</dd>
<dt>•</dt>
<dd>Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC [see <span class="Bold"><a href="#_Ref">WARNINGS AND PRECAUTIONS (5.1)</a>].</span>
</dd>
<dt>•</dt>
<dd>Tri-Estarylla™ does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
<dt>•</dt>
<dd>Tri-Estarylla™ is not to be used during pregnancy; if pregnancy occurs during use of  Tri-Estarylla™  instruct the patient to stop further use [see <span class="Bold"><a href="#ID_2de866ff-010f-46ac-a02f-3ce4c0912073">WARNINGS AND PRECAUTIONS (5.8)</a>].</span>
</dd>
<dt>•</dt>
<dd>Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed [see <span class="Bold"><a href="#ID_a647c8d9-7db4-4413-a452-bd61b24e6c86">DOSAGE AND ADMINISTRATION (2.2)</a>].</span>
</dd>
<dt>•</dt>
<dd>Use a back-up or alternative method of contraception when enzyme inducers are used with Tri-Estarylla™  [see <span class="Bold"><a href="#ID_d96028c3-b509-41c5-8d82-8ddb838cbf7f">DRUG INTERACTIONS (7.1)</a>].</span>
</dd>
<dt>•</dt>
<dd>COCs may reduce breast milk production; this is less likely to occur if breastfeeding is well established [see <span class="Bold"><a href="#ID_47e5d169-096a-42cf-b978-b50d05e93b0f">USE IN SPECIFIC POPULATIONS (8.3)</a>].</span>
</dd>
<dt>•</dt>
<dd>Women who start COCs postpartum, and who have not yet had a period, should use an additional method of contraception until they have taken an active tablet for 7 consecutive days [see <span class="Bold"><a href="#ID_a647c8d9-7db4-4413-a452-bd61b24e6c86">DOSAGE AND ADMINISTRATION (2.2)</a>].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> may occur. Consider pregnancy in the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> at the time of the first missed period. Rule out pregnancy in the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> in two or more consecutive cycles [see <span class="Bold"><a href="#ID_2b3212a1-069e-4552-8496-ea295921d660">WARNINGS AND PRECAUTIONS (5.7)</a>].</span>
</dd>
</dl>
<p>Manufactured by Laboratorios Leon Farma S.A., Spain for</p>
<p>Sandoz Inc., Princeton, NJ 08540</p>
<p>Rev. May 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_02834127-28f0-4315-8451-a51f0f793d53"></a><a name="section-16"></a><p></p>
<h1>Patient Package Insert</h1>
<p class="First"><span class="Bold">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP) </span></p>
<p><span class="Bold">(</span><span class="Bold">nor-JES-ti-mate</span><span class="Bold">, ETH-i-nil es-tra-DYE-ol)</span></p>
<p><span class="Bold">What is the most important information I should know about Tri-Estarylla™?</span></p>
<p><span class="Bold">Do not use Tri-Estarylla™ if you smoke cigarettes and are over 35 years old. </span>Smoking increases your risk of serious cardiovascular side effects from hormonal birth control pills, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, blood clots or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. This risk increases with age and the number of cigarettes you smoke.</p>
<p><span class="Bold">What is Tri-Estarylla™?</span></p>
<p><span class="Bold">Tri-Estarylla™ </span>is a birth control pill (oral contraceptive) used by women to prevent pregnancy.</p>
<p>Tri-Estarylla™ is also used to treat moderate <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> in females 15 years of age and older, who have no known history of allergies or problems taking birth control pills, and have started their menstrual cycle (“period?). Tri-Estarylla™ should only be used to treat <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in women who want to take birth control pills to prevent pregnancy.</p>
<p><span class="Bold">How does Tri-Estarylla™ work for contraception?</span></p>
<p>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.</p>
<p>Based on the results of clinical studies, about 1 out of 100 women may get pregnant during the first year they use Tri-Estarylla™.</p>
<p>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</p>
<div class="Figure">
<a name="id-803548778"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-04.jpg">
</div>
<p><span class="Bold">Who should not take Tri-Estarylla™?</span></p>
<p><span class="Bold">Do not take Tri-Estarylla™ if you: </span></p>
<dl>
<dt>•</dt>
<dd>smoke and are over 35 years of age</dd>
<dt>•</dt>
<dd>had blood clots in your arms, legs, lungs, or eyes</dd>
<dt>•</dt>
<dd>had a problem with your blood that makes it clot more than normal</dd>
<dt>•</dt>
<dd>have certain heart valve problems or irregular heart beat that increases your risk of having blood clots</dd>
<dt>•</dt>
<dd>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>•</dt>
<dd>had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></dd>
<dt>•</dt>
<dd>have high blood pressure that cannot be controlled by medicine</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with kidney, eye, nerve, or blood vessel damage</dd>
<dt>•</dt>
<dd>have certain kinds of severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or changes in vision, or any <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> if you are over 35 years of age</dd>
<dt>•</dt>
<dd>have liver problems, including <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></dd>
<dt>•</dt>
<dd>have any unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></dd>
<dt>•</dt>
<dd>are pregnant</dd>
<dt>•</dt>
<dd>had breast cancer or any cancer that is sensitive to female hormones</dd>
</dl>
<p><span class="Bold">If any of these conditions happen while you are taking Tri-Estarylla™, stop taking Tri-Estarylla™ right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking Tri-Estarylla™. </span></p>
<p><span class="Bold">What should I tell my healthcare provider before taking Tri-Estarylla™?</span></p>
<p><span class="Bold">Tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>are pregnant or think you may be pregnant</dd>
<dt>•</dt>
<dd>are depressed now or have been depressed in the past</dd>
<dt>•</dt>
<dd>had yellowing of your skin or eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) caused by pregnancy (<span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span> of pregnancy)</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. Tri-Estarylla™ may decrease the amount of breast milk you make. A small amount of the hormones in Tri-Estarylla™ may pass into your breast milk. Talk to your healthcare provider about the best birth control method for you while breastfeeding.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal supplements.</p>
<p>Tri-Estarylla™may affect the way other medicines work, and other medicines may affect how well Tri-Estarylla™works.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Tri-Estarylla™?</span></p>
<p><span class="Bold">Read the Instructions for Use</span> at the end of this Patient Information<span class="Bold">. </span></p>
<p><span class="Bold">What are the possible serious side effects of Tri-Estarylla™?</span></p>
<dl>
<dt>•</dt>
<dd>Like pregnancy, Tri-Estarylla™ may cause serious side effects, including blood clots in your lungs, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some other examples of serious blood clots include blood clots in the legs or eyes.</dd>
</dl>
<p>Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious blood clots are more likely to happen when you:</p>
<dl>
<dt>•</dt>
<dd>first start taking birth control pills</dd>
<dt>•</dt>
<dd>restart the same or different birth control pills after not using them for a month or more</dd>
</dl>
<p><span class="Bold">Call your healthcare provider or go to a hospital emergency room right away if you have:</span></p>
<table>
<col width="43%">
<col width="44%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Toprule" valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span> that will not go away</dd>
<dt>•</dt>
<dd>sudden severe <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>•</dt>
<dd>sudden change in vision or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></dd>
</dl></td>
<td class="Botrule Toprule" valign="top"><dl>
<dt>•</dt>
<dd>a sudden, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> unlike your usual <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your arm or leg</dd>
<dt>•</dt>
<dd>trouble speaking</dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Bold">Other serious side effects include:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">liver problems, including: </span><dl>
<dt>1.</dt>
<dd>rare <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></dd>
<dt>2.</dt>
<dd><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (<span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>), especially if you previously had <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> of pregnancy. Call your healthcare provider if you have yellowing of your skin or eyes.</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">high</span><span class="Bold"> blood pressure.</span> You should see your healthcare provider for a yearly check of your blood pressure.</dd>
<dt>•</dt>
<dd><span class="Bold">gallbladder problems</span></dd>
<dt>•</dt>
<dd><span class="Bold">changes in the sugar and fat (<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides) levels in your blood</span></dd>
<dt>•</dt>
<dd><span class="Bold">new or worsening <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> including <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span></span></dd>
<dt>•</dt>
<dd>
<span class="Bold">irregular</span><span class="Bold"> or unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> and spotting between your menstrual periods, especially during the first 3 months of taking Tri-Estarylla™. </span>
</dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">possible cancer in your breast and cervix</span></dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></span><span class="Bold"> of your skin especially around your mouth, eyes, and in your throat (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>).</span> Call your healthcare provider if you have a swollen face, lips, mouth tongue or throat, which may lead to difficulty swallowing or breathing. Your chance of having <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> is higher if you have a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold">dark</span><span class="Bold"> patches of skin around your forehead, nose, cheeks and around your mouth, especially during pregnancy (<span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span>).</span> Women who tend to get <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span> should avoid spending a long time in sunlight, tanning booths, and under sun lamps while taking Tri-Estarylla™. Use sunscreen if you have to be in the sunlight.</dd>
</dl>
<p><span class="Bold">What are the most common side effects of Tri-Estarylla™?</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement or discharge</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, and gas</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span> and discharge</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></dd>
<dt>•</dt>
<dd>changes in weight</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></dd>
</dl>
<p>These are not all the possible side effects of Tri-Estarylla™. For more information, ask your healthcare provider or pharmacist.</p>
<p>You may report side effects to the Sandoz Inc., 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.FDA.GOV/Medwatch.</p>
<p><span class="Bold">What else should I know about taking Tri-Estarylla™?</span></p>
<dl>
<dt>•</dt>
<dd>If you are scheduled for any lab tests, tell your healthcare provider you are taking Tri-Estarylla™. Certain blood tests may be affected by Tri-Estarylla™.</dd>
<dt>•</dt>
<dd>Tri-Estarylla™ does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl>
<p><span class="Bold">How should I store Tri-Estarylla™?</span></p>
<dl>
<dt>•</dt>
<dd>Store Tri-Estarylla™ at room temperature between 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Keep Tri-Estarylla™ and all medicines out of the reach of children.</dd>
<dt>•</dt>
<dd>Store away from light.</dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of Tri-Estarylla™.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Tri-Estarylla™ for a condition for which it was not prescribed. Do not give Tri-Estarylla™ to other people, even if they have the same symptoms that you have.</p>
<p>This Patient Information summarizes the most important information about Tri-Estarylla™ . You can ask your pharmacist or healthcare provider for information about Tri-Estarylla™ that is written for health professionals<span class="Italics">. </span></p>
<p>For more information, call  Sandoz Inc. at 1-800-525-8747</p>
<p><span class="Bold">Do birth control pills cause cancer?</span></p>
<p>Birth control pills do not seem to cause breast cancer. However, if you have breast cancer now, or have had it in the past, do not use birth control pills because some breast cancers are sensitive to hormones.</p>
<p>Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</p>
<p><span class="Bold">What if I want to become pregnant?</span></p>
<p>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.</p>
<p><span class="Bold">What should I know about my period when taking Tri-Estarylla™?</span></p>
<p>Your periods may be lighter and shorter than usual. Some women may miss a period. Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting may happen while you are taking Tri-Estarylla™, especially during the first few months of use. This usually is not a serious problem. It is important to continue taking your pills on a regular schedule to prevent a pregnancy.</p>
<p><span class="Bold">What are the ingredients in Tri-Estarylla™?</span></p>
<p><span class="Bold">Active ingredients:</span>  Each white, light-blue, and blue pill contains norgestimate and ethinyl estradiol.</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p><span class="Bold"><span class="Italics">White pills:</span></span> crospovidone, lactose anhydrous, magnesium stearate, and pregelatinized starch.</p>
<p><span class="Bold"><span class="Italics">Light-blue pills:</span></span> crospovidone, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch.</p>
<p><span class="Bold"><span class="Italics">Blue pills:</span></span> crospovidone, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch.</p>
<p><span class="Bold"><span class="Italics">Green pills:</span></span>  crospovidone, D &amp;C Yellow No.10 aluminum Lake, FD &amp; C Blue No.2 lake, lactose anhydrous, magnesium stearate, and pregelatinized starch</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="ID_c7937fa9-e155-4cb5-a049-fd76adc090ce"></a><a name="section-17"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First"><span class="Bold">Tri-Estarylla™ (norgestimate and ethinyl estradiol tablets, USP) </span></p>
<p><span class="Bold">Important Information about taking Tri-Estarylla™</span></p>
<dl>
<dt>•</dt>
<dd>Take 1 pill every day at the same time. Take the pills in the order directed on your <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</dd>
<dt>•</dt>
<dd>Do not skip your pills, even if you do not have sex often. If you miss pills (including starting the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack late) <span class="Bold">you could get pregnant. </span>The more pills you miss, the more likely you are to get pregnant.</dd>
<dt>•</dt>
<dd>If you have trouble remembering to take Tri-Estarylla™, talk to your healthcare provider. When you first start taking Tri-Estarylla™, spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in between your periods may occur. Contact your healthcare provider if this does not go away after a few months.</dd>
<dt>•</dt>
<dd>You may feel sick to your stomach (nauseous), especially during the first few months of taking Tri-Estarylla™. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If your <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> does not go away, call your healthcare provider.</dd>
<dt>•</dt>
<dd>Missing pills can also cause spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills (see <span class="Bold"><a href="#_Ref">What should I do if I miss any Tri-EstaryllaTM pills?</a></span> below), you could also feel a little sick to your stomach.</dd>
<dt>•</dt>
<dd>It is not uncommon to miss a period. However, if you miss a period and have not taken Tri-Estarylla™ according to directions, or miss 2 periods in a row, or feel like you may be pregnant, call your healthcare provider. If you have a <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy test</span>, you should stop taking Tri-Estarylla™.</dd>
<dt>•</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> within 3 to 4 hours of taking your pill, take another pill of the same color from your extra pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. If you do not have an extra pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, take the next pill in your pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Continue taking all your remaining pills in order. Start the first pill of your next pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack the day after finishing your current pill <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. This will be 1 day earlier than originally scheduled. Continue on your new schedule.</dd>
<dt>•</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> for more than 1 day, your birth control pills may not work as well. Use an additional birth control method, like condoms and a spermicide, until you check with your healthcare provider.</dd>
<dt>•</dt>
<dd>Stop taking Tri-Estarylla™ at least 4 weeks before you have major surgery and do not restart after the surgery without asking your healthcare provider. Be sure to use other forms of contraception (like condoms and spermicide) during this time period.</dd>
</dl>
<p><span class="Bold">Before you start taking Tri-Estarylla™:</span></p>
<dl>
<dt>•</dt>
<dd>Decide what time of day you want to take your pill. It is important to take it at the same time every day and in the order as directed on your <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</dd>
<dt>•</dt>
<dd>Have backup contraception (condoms and spermicide) available and if possible, an extra full <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of pills as needed.</dd>
</dl>
<p><span class="Bold">When should I start taking Tri-Estarylla™?</span></p>
<p><span class="Bold">If you start taking Tri-Estarylla™ and you have not used a hormonal birth control method before:</span></p>
<dl>
<dt>•</dt>
<dd>There are 2 ways to start taking your birth control pills. You can either start on a Sunday (Sunday Start) or on the first day (Day 1) of your natural menstrual period (Day 1 Start). Your healthcare provider should tell you when to start taking your birth control pill.</dd>
<dt>•</dt>
<dd>If you use the Sunday Start, use non-hormonal back-up contraception such as condoms and spermicide for the first 7 days that you take Tri-Estarylla™. You do not need back-up contraception if you use the Day 1 Start.</dd>
</dl>
<p><span class="Bold">If you start taking Tri-Estarylla™ and you are switching from another birth control pill:</span></p>
<dl>
<dt>•</dt>
<dd>Start your new Tri-Estarylla™ pack on the same day that you would start the next pack of your previous birth control method.</dd>
<dt>•</dt>
<dd>Do not continue taking the pills from your previous birth control pack.</dd>
</dl>
<p><span class="Bold">If you start taking Tri-Estarylla™ and previously used a vaginal ring or transdermal patch:</span></p>
<dl>
<dt>•</dt>
<dd>Start using Tri-Estarylla™ on the day you would have reapplied the next ring or patch.</dd>
</dl>
<p><span class="Bold">If you start taking Tri-Estarylla™ and you are switching from a progestin-only method such as an implant or injection:</span></p>
<dl>
<dt>•</dt>
<dd>Start taking Tri-Estarylla™ on the day of removal of your implant or on the day when you would have had your next injection.</dd>
</dl>
<p><span class="Bold">If you start taking Tri-Estarylla™ and you are switching from an intrauterine device or system (IUD or IUS):</span></p>
<dl>
<dt>•</dt>
<dd>Start taking Tri-Estarylla™ on the day of removal of your IUD or IUS.</dd>
<dt>•</dt>
<dd>You do not need back-up contraception if your IUD or IUS is removed on the first day (Day 1) of your period. If your IUD or IUS is removed on any other day, use non-hormonal back-up contraception such as condoms and spermicide for the first 7 days that you take Tri-Estarylla™.</dd>
</dl>
<p><span class="Bold">Keep a calendar to track your period</span><span class="Bold">:</span><br><span class="Bold">If this is the first time</span> you are taking birth control pills, read, "<span class="Bold">When should I start taking Tri-Estarylla™?"</span> above. Follow these instructions for either a Sunday <span class="Bold">Start or a Day 1 Start</span>.</p>
<p><span class="Bold">Sunday Start</span><span class="Bold">:</span><br>You will use a Sunday Start if your healthcare provider told you to take your first pill on a Sunday.</p>
<dl>
<dt>•</dt>
<dd>Take pill <span class="Bold">1</span> on the Sunday <span class="Bold">after your period starts.</span>
</dd>
<dt>•</dt>
<dd>If your period starts on a Sunday, take pill "1" that day and refer to Day <span class="Bold">1</span> Start instructions below.</dd>
<dt>•</dt>
<dd>Take <span class="Bold">1 </span>pill every day in the order on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack at the same time each day for <span class="Bold">28</span> days.</dd>
<dt>•</dt>
<dd>After taking the last pill on <span class="Bold">Day 28</span> from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, start taking the first pill from a new <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, on the same day of the week as the first <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack (Sunday). Take the first pill in the new pack whether or not you are having your period.</dd>
<dt>•</dt>
<dd>Use non-hormonal back-up contraception such as condoms and spermicide for the first 7 days of the first cycle that you take Tri-Estarylla™.</dd>
</dl>
<p><span class="Bold">Day 1 Start</span><span class="Bold">:</span><br>You will use a <span class="Bold">Day 1</span> Start if your doctor told you to take your first pill (Day 1) on the <span class="Bold">first day of your period.</span></p>
<dl>
<dt>•</dt>
<dd>Take <span class="Bold">1</span> pill every day in the order of the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, at the same time each day, for <span class="Bold">28</span> days.</dd>
<dt>•</dt>
<dd>After taking the last pill on <span class="Bold">Day 28</span> from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, start taking the first pill from a new pack, on the same day of the week as the first pack. Take the first pill in the new pack whether or not you are having your period.</dd>
</dl>
<p><span class="Bold">Tri-Estarylla™ comes in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Read the instructions below for using your <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.</span></p>
<p><span class="Bold">BEFORE YOU START TAKING YOUR PILLS:</span></p>
<dl>
<dt></dt>
<dd><dl>
<dt>1.</dt>
<dd>BE SURE TO READ THESE DIRECTIONS:</dd>
</dl></dd>
</dl>
<p>Before you start taking your pills.</p>
<p>Anytime you are not sure what to do.</p>
<p>2.THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.<br>If you miss pills you could get pregnant. This includes starting the pack late.</p>
<p>The more pills you miss, the more likely you are to get pregnant.</p>
<p>3.MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 to 3 PACKS OF PILLS. If you feel sick to your stomach or have spotting or light <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your healthcare professional.</p>
<p>4.MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills.</p>
<p>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</p>
<p>5.IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, OR IF YOU TAKE SOME MEDICINES, Including some antibiotics, your pills may not work as well.</p>
<p>Use a back-up method (such as a condom or spermicide) until you check with your healthcare professional.</p>
<p>6.IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your healthcare professional about how to make pill-taking easier or about using another method of birth control.</p>
<p>7.IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your healthcare professional.</p>
<p><span class="Bold">BEFORE YOU START TAKING YOUR PILLS</span></p>
<p>1.DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.<br>It is important to take it at about the same time every day.</p>
<p>2.LOOK AT YOUR PILL PACK</p>
<dl>
<dt> </dt>
<dd>The pill pack has 21 "active" pills (with hormones) to take for 3 weeks. This is followed by 1 week of "reminder" green pills (without hormones).</dd>
</dl>
<p>3.ALSO FIND:</p>
<p>1.where on the pack to start taking pills,</p>
<p>2.in what order to take the pills (follow the arrows)</p>
<p>3.the week numbers as shown in the diagram below.</p>
<div class="Figure">
<a name="ID0EK4LM"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-05.jpg">
</div>
<dl>
<dt> </dt>
<dd>4.BE SURE YOU HAVE READY AT ALL TIMES:</dd>
</dl>
<p>ANOTHER KIND OF BIRTH CONTROL (such as a condom or spermicide) to use as a back-up method in case you miss pills.</p>
<p>AN EXTRA, FULL PILL PACK.</p>
<p><span class="Bold">What should I do if I miss any Tri-Estarylla™ pills?</span></p>
<p><span class="Bold">If you miss 1 pill in Weeks 1, 2, or 3, follow these steps:</span></p>
<dl>
<dt>•</dt>
<dd>Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</dd>
<dt>•</dt>
<dd>Then continue taking 1 pill every day until you finish the pack.</dd>
<dt>•</dt>
<dd>You do not need to use a back-up birth control method if you have sex.</dd>
</dl>
<p><span class="Bold">If you miss 2 pills in Week 1 or Week 2 of your pack, follow these steps:</span></p>
<dl>
<dt>•</dt>
<dd>Take the 2 missed pills as soon as possible and the next 2 pills the next day.</dd>
<dt>•</dt>
<dd>Then continue to take 1 pill every day until you finish the pack.</dd>
<dt>•</dt>
<dd>Use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first 7 days after missing your pills.</dd>
</dl>
<p><span class="Bold">If you miss 2 pills in a row in Week 3, or you miss 3 or more pills in a row during Weeks 1, 2, or 3 of the pack, follow these steps:</span></p>
<p><span class="Bold">If you are a Day 1 Starter:</span></p>
<dl>
<dt>•</dt>
<dd>Throw out the rest of the pill pack and start a new pack that same day.</dd>
<dt>•</dt>
<dd>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare provider because you might be pregnant.</dd>
<dt>•</dt>
<dd>You could become pregnant if you have sex during the first 7 days after you restart your pills. You MUST use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first 7 days after you restart your pills.</dd>
</dl>
<p><span class="Bold">If you are a Sunday Starter:</span></p>
<dl>
<dt>•</dt>
<dd>Keep taking 1 pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of pills that same day.</dd>
<dt>•</dt>
<dd>Use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first 7 days after you restart your pills.</dd>
</dl>
<p><span class="Bold">If you have any questions or are unsure about the information in this leaflet, call your healthcare provider.</span></p>
<p>This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.  </p>
<p><span class="Bold">Tri-Estarylla<span class="Sup">TM</span></span> is a trademarks of Sandoz Inc.</p>
<p>The brands listed are the registered trademark of their respective owners and are not trademarks of Sandoz Inc.</p>
<p>Manufactured by Laboratorios Leon Farma S.A., Spain for</p>
<p>Sandoz Inc., Princeton, NJ  08540</p>
<p>Rev. May 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_95cef127-5ee9-4b35-8360-3617224ad636"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 0781-4060-15</span></p>
<p><span class="Bold">3 Units</span></p>
<p><span class="Bold">Tri-Estarylla<span class="Sup">TM</span></span></p>
<p><span class="Bold">(Norgestimate and Ethinyl Estradiol Tablets, USP)</span></p>
<p><span class="Bold">0.18 mg/0.35 mg, 0.0215 mg/0.35 mg, 0.25 mg/0.35 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">3 x 28 tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card</span></p>
<div class="Figure">
<a name="id67775989"></a><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7841b848-ba6b-41b8-8c32-fde3eda6e8e6&amp;name=aa4a6b20-3a3a-42e4-9f95-813b699aabd8-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRI-ESTARYLLA 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-4060</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-4060-15</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>ORTHO TRI CYCLEN 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (norgestimate) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.180 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ethinyl estradiol) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.035 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ;T2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090793</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>ORTHO TRI CYCLEN 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (norgestimate) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.215 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ethinyl estradiol) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.035 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (light blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ;T3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090793</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>ORTHO TRI CYCLEN 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (norgestimate) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ethinyl estradiol) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.035 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ;T4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090793</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">inert tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SZ;J1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090793</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090793</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sandoz Inc
							(110342024)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aa4a6b20-3a3a-42e4-9f95-813b699aabd8</div>
<div>Set id: 7841b848-ba6b-41b8-8c32-fde3eda6e8e6</div>
<div>Version: 5</div>
<div>Effective Time: 20150520</div>
</div>
</div> <div class="DistributorName">Sandoz Inc</div></p>
</body></html>
